https://bio.nikkeibp.co.jp/atcl/news/p1/23/09/05/11051/

Takara Bio has announced that it has established a technology to rapidly produce chimeric antigen receptor T cells (CAR-T cells). By shortening the culture period to two days, it is possible to produce CAR-T cells with higher cytotoxic activity than usual, and the company plans to utilize this in its CDMO business. The company’s CDMO business has strengths in manufacturing cultured cells, mRNA drug substances, viral vectors, etc. for cell medicine and gene therapy. The company also undertakes contract manufacturing of GMP/GCTP grade CAR-T cells, and has recently developed technology to reduce manufacturing costs and improve the therapeutic efficacy of CAR-T preparations.